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María Ángeles Clari1, Estela Giménez1, Gerardo Aguilar2, Isabel Corrales1, Juan Alberola3 and David Navarro1,3*There is an increasing appreciation for the potential
clinical value of the quantitation of cytomegalovirus
(CMV) DNA in the lower respiratory tract in critic-
ally ill patients lacking canonical immunosuppression,
in view of the possible pathogenic role of CMV in
these patients [1]. No data have been published on
the analytical performance of real-time PCR assays
for this purpose.
We present our data on the performance of the
COBAS® AmpliPrep/COBAS® TaqMan CMV PCR
Assay (Roche Diagnostics, Mannheim, Germany) for
the quantitation of CMV DNA in tracheal aspirates
(TA). This CMV PCR assay has been approved re-
cently by the US Food and Drug Administration for
use with plasma specimens [2]. We chose TA for
the analyses because of the simplicity of their col-
lection in critically ill patients undergoing mechan-
ical ventilation.
We pooled TA obtained from five ICU patients
with undetectable CMV DNA levels in TA and in
plasma specimens [3]. The pool was fluidized by
treatment with N-acetyl cysteine (1 % in PBS) at a 1:1
volume ratio (vortexed for 30 seconds, incubated for
10 minutes at room temperature and centrifuged at
1,600 rpm for 10 minutes). The pellet was then resus-
pended with distilled water to obtain the initial vol-
ume. Four aliquot portions were spiked with different
quantities (2.69, 3.69, 4.69, and 5.69 log10 IU/ml) of
the First World Health Organization International
Standard for CMV (National Institute for Biological* Correspondence: david.navarro@uv.es
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testing pools were assayed in heptuplicate on three
consecutive days.
The fitted regression line between copies/ml and
IU/ml for tracheal aspirates was y = 1.0013x – 0.0517
(R2 = 0.999). According to our calculations, 1 copy/ml
was equated to 0.90 IU/ml (similar to that for plasma
specimens [5]). The overall intra-assay and inter-assay
coefficients of variation were 8.2 % (95 % confidence
interval (CI), –0.6 to 17.0 %) and 10.77 % (95 % CI,
1.69 to 19.8 %), which are slightly higher than those
for plasma specimens [5]. The analytical performance
of the assay was analyzed with clinical samples con-
taining different copy numbers of CMV DNA. The
data are shown in Table 1. The overall intra-assay
and inter-assay coefficients of variation were 14.0 %
(95 % CI, 9.8 to 18.1 %) and 15.4 % (95 % CI, 12.1 to
18.8 %), respectively.
Our data indicate that this CMV PCR assay per-
forms well with fluidized TA containing low to
intermediate CMV DNA loads (between 500 and
50,000 copies/ml), and may therefore be used for
monitoring CMV replication in the lower respira-
tory tract in critically ill patients undergoing mech-
anical ventilation.
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Table 1 Performance of the cytomegalovirus PCR assay for quantitation of cytomegalovirus DNA load in tracheal
aspirates
Group (number of specimens)a Range of CMV DNA loads (copies/ml)b % Coefficient of variation (95 % confidence interval)
Intra-assay Inter-assay
A (10) 150 to 851 14.0 (9.8 to 18.7) 15.4 (12.1 to 18.8)
B (10) 1,234 to 8,781 10.6 (7.8 to 14.0) 16.2 (11.2 to 21.5)
C (10) 11,013 to 56,000 11.7 (4.9 to 18.5) 12.8 (7.3 to 18.3)
A + B + C (30) 150 to 56,000 14.0 (9.8 to 18.1) 15.4 (12.1 to 18.8)
CMV PCR assay, COBAS® AmpliPrep/COBAS® TaqMan Cytomegalovirus PCR Assay (Roche Diagnostics, Mannheim, Germany). aTracheal aspirates were obtained
from 20 patients with septic shock of abdominal origin admitted to the ICU. On the basis of their cytomegalovirus (CMV) DNA content, the specimens were
grouped into three categories: A, between 150 and 1,000 copies/ml; B, between 1,000 and 10,000 copies/ml; and C, >10,000 copies/ml. The specimens were
divided into the above referred groups based on two criteria: the precision of the Roche PCR assay for plasma specimens was shown to vary depending upon the
CMV DNA content – in this sense, the coefficient of variation was maximum for specimens containing <1,000 copies/ml, minimum for those containing >10,000
copies/ml, and intermediate for specimens containing CMV DNA loads between 1,000 and 10,000 copies/ml [5]; and the majority of tracheal aspirates from
critically ill patients displaying an episode of active CMV infection contain CMV DNA loads <1,000 copies/ml, so the knowledge of the performance of the PCR
assay with specimens containing CMV DNA loads within this range (150 to 1,000 copies/ml) is of particular clinical interest. Only occasionally, tracheal aspirates
contain >10,000 copies/ml. bAs determined by the CMV PCR assay. This PCR assay targets the CMV UL54 gene (DNA polymerase) and displays a limit of detection
of 100 copies/ml (91 IU/ml), a limit of quantification of 150 copies/ml (164 IU/ml), and a linear quantification range from 150 to 10,000,000 (2.18 to 7.0 log10)
copies/ml for plasma specimens.
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